COVERAGE BY STATE FOR SIMPONI ARIA® (golimumab)*†
Coverage by state
*Data as of January 1, 2017. Based on third-party validated assessment on a near census of commercial insurers that includes approximately 97% of commercially insured patients.
†First-line biologic: Brand-name drug that does not require trial on another biologic product prior to utilization.
The information provided represents no statement, promise, or guarantee of Janssen Biotech, Inc., concerning levels of reimbursement, payment, or charge. Please consult your payer organization with regard to local or actual coverage, reimbursement policies, and determination processes.
Information is subject to change without notice. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of Janssen Biotech, Inc.
Don’t see your patient’s insurer? Speak with a representative at Janssen CarePath to discuss even more options. There’s a way.
Providing access, affordability, and treatment support to help your patients start and stay on Janssen medications as prescribed
Call us. We’re here to help.